This study aims to evaluate the predictive value of the tumor vascular normalization score for the efficacy of neoadjuvant therapy in HER-2-positive breast cancer and explore its potential as a predictive biomarker. Through longitudinal observation of HER-2-positive breast cancer patients receiving standard treatment, we will analyze the correlation between vascular normalization scores and treatment responses (including objective response rate [ORR] and pathological complete response [pCR]) to optimize individualized therapeutic strategies. Additionally, an exploratory investigation will assess the impact of ginsenoside-containing formulations (e.g., Jinxing Capsule, Shenyi Capsule, Yiqi Jianpi Oral Liquid) on tumor vasculature and neoadjuvant therapy outcomes in HER-2-positive breast cancer, providing scientific insights for complementary therapeutic interventions.

Inclusion Criteria:

• Female breast cancer patients aged ≥18 years planned for neoadjuvant therapy.
• Histopathologically confirmed HER2-positive status (IHC 3+ or IHC 2+ with positive FISH confirmation).
• Mentally competent, no psychiatric disorders, with good compliance to treatment and follow-up.
• Voluntarily participate and provide written informed consent.

Exclusion Criteria:

• HER2-negative breast cancer.
• Pregnant, planning pregnancy, or lactating women.
• History of allergic predisposition or known/suspected allergy to study drugs.
• Participation in other clinical trials within the past 4 weeks or planned enrollment.
• Other conditions deemed ineligible by the investigator.

Female HER2 positive breast cancer patients